FDA Grants Priority Review to Pegcetacoplan for C3G and IC-MPGN | Docwire News
The FDA has granted Priority Review to pegcetacoplan (Empaveli) to treat C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).